{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Idiopathic+Focal+Segmental+Glomerulosclerosis&page=2",
    "query": {
      "condition": "Idiopathic Focal Segmental Glomerulosclerosis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Idiopathic+Focal+Segmental+Glomerulosclerosis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T12:07:23.913Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01613118",
      "title": "Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "RE-021 (Sparsentan)",
          "type": "DRUG"
        },
        {
          "name": "Irbesartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Travere Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "8 Years to 75 Years"
      },
      "enrollment_count": 109,
      "start_date": "2014-03",
      "completion_date": "2024-03-25",
      "has_results": true,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-07-24T12:07:23.913Z",
      "location_count": 28,
      "location_summary": "San Diego, California • Torrance, California • Denver, Colorado + 19 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01613118"
    },
    {
      "nct_id": "NCT00464321",
      "title": "Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "GC1008",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-05",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2014-03-19",
      "last_synced_at": "2026-07-24T12:07:23.913Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Rochester, Minnesota • New Hyde Park, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00464321"
    },
    {
      "nct_id": "NCT04983888",
      "title": "Obinutuzumab in Primary FSGS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-11-17",
      "completion_date": "2025-06-16",
      "has_results": true,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-07-24T12:07:23.913Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04983888"
    },
    {
      "nct_id": "NCT06466135",
      "title": "Study of WAL0921 in Patients With Glomerular Kidney Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Nephropathies",
        "Primary Focal Segmental Glomerulosclerosis",
        "Minimal Change Disease",
        "Primary Immunoglobulin A Nephropathy",
        "Primary Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "WAL0921",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walden Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 96,
      "start_date": "2024-07-02",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-07-24T12:07:23.913Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hinsdale",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06466135"
    },
    {
      "nct_id": "NCT00255398",
      "title": "Kidney Disease Biomarkers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Disease",
        "Glomerular Disease",
        "Idiopathic Nephrotic Syndrome",
        "Focal Segmental Glomerulosclerosis",
        "Collapsing Glomerulopathy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2005-11-10",
      "completion_date": "2014-12-03",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-07-24T12:07:23.913Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00255398"
    },
    {
      "nct_id": "NCT07220083",
      "title": "A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "BI 764198",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 286,
      "start_date": "2026-02-16",
      "completion_date": "2029-01-24",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-07-24T12:07:23.913Z",
      "location_count": 66,
      "location_summary": "Alabaster, Alabama • Huntsville, Alabama • Surprise, Arizona + 56 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220083"
    },
    {
      "nct_id": "NCT00814255",
      "title": "Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril, losartan, and atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "galactose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "1 Year to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2008-12",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2016-07-11",
      "last_synced_at": "2026-07-24T12:07:23.913Z",
      "location_count": 17,
      "location_summary": "Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00814255"
    },
    {
      "nct_id": "NCT01665391",
      "title": "A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "fresolimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2012-08",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2015-08-26",
      "last_synced_at": "2026-07-24T12:07:23.913Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01665391"
    },
    {
      "nct_id": "NCT05599815",
      "title": "Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nephrotic Syndrome"
      ],
      "interventions": [
        {
          "name": "ADX-629",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aldeyra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-01",
      "completion_date": "2023-05",
      "has_results": false,
      "last_update_posted_date": "2024-04-17",
      "last_synced_at": "2026-07-24T12:07:23.913Z",
      "location_count": 11,
      "location_summary": "Northridge, California • Aurora, Colorado • Lauderdale Lakes, Florida + 8 more",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lauderdale Lakes",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bremen",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05599815"
    },
    {
      "nct_id": "NCT02000440",
      "title": "A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glomerulosclerosis, Focal Segmental"
      ],
      "interventions": [
        {
          "name": "Losmapimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 17,
      "start_date": "2014-07-01",
      "completion_date": "2016-05-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-12",
      "last_synced_at": "2026-07-24T12:07:23.913Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Stanford, California • New Orleans, Louisiana + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02000440"
    }
  ]
}